In various healthcare settings, acute kidney disease (AKD) has seen a rising incidence 4,5 , with associated heightened risks of all-cause mortality, end-stage kidney disease, and chronic kidney disease (CKD) 6
In a separate review of 135 patients, the median age of onset of symptoms was 5 years with a range from birth to 68 years
Common adverse effects include gastrointestinal symptoms, particularly nausea (30-50% of patients), vomiting, diarrhea, and constipation
If the pleiotropic effect class is confirmed for the triple agonist, there is a potential amplification of these benefits via the glucagon lever
Generally well tolerated, with injection-site reactions the most common adverse event